Otsuka Korea begins SWAT study

Otsuka Korea said that since the end of October, it has began conducting its local SWAT (SWitching of Abilify Trial) study to evaluate the safety and efficacy of Abilify, including its tolerability, which was launched earlier this year, after physicians prescribed Abilify to patients with schizophrenia, schizoaffective and schizophreniform disorders who needed to switch treatment because of lac...